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Abstract All-trans retinoic acid (ATRA) is known to reverse
the anatomic and physiologic signs of pulmonary emphysema.
However, the origin of the progenitor cells involved in this lung
regeneration remains unclear. Recently, it was shown that bone
marrow could be the source of progenitor cells for several cell
types. Mice with elastase-induced emphysema were treated with
ATRA, granulocyte colony-stimulating factor (G-CSF), or a
combination of both. ATRA or G-CSF promoted lung regener-
ation and increased bone marrow-derived cell (BMC) numbers
in alveoli. Combined treatment of both had an additive e¡ect,
which indicated that BMC mobilization might be important in
lung regeneration.
( 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Pulmonary emphysema is one of the most common reasons
for ill health worldwide, and is ranked as a frequent cause of
death. The pathophysiologic changes associated with emphy-
sema are the progressive destruction of lung parenchyma and
reduced surface area available for gas exchange, which result
in inadequate oxygenation. Because adult human lungs can-
not spontaneously grow or regenerate, pulmonary emphysema
is considered to be a progressive and irreversible disease. In
1997, Massaro et al. showed that all-trans retinoic acid
(ATRA) reversed anatomic and physiologic signs in an animal
pulmonary emphysema model [1]. ATRA is known to activate
genes involved in lung development and promote alveolar
septation and lung growth. However, the origin of the pro-
genitor cells that regenerated the damaged lung parenchyma
remains unclear.
It has recently been shown that the bone marrow is the
source of progenitor cells for various cell types, including
endothelial cells [2], epithelial cells [3^5], myocytes [6], and
neurons [7]. Also, the mobilization of bone marrow-derived
cells (BMCs) by cytokines, such as granulocyte colony-stim-
ulating factor (G-CSF), has been shown to be involved in the
repair of the infarcted heart [8]. Therefore, we hypothesized
that BMCs may contribute to lung regeneration in the em-
physematous lung. The aims of this study were to examine the
e¡ect of hematopoietic cell mobilization in lung regeneration,
and to evaluate the distribution of BMCs after regeneration.
2. Materials and methods
2.1. Lethal irradiation and reconstitution of bone marrow
Mice transgenic for enhanced green £uorescent protein (GFP) on a
C57BL/6 strain background were established at the Research Institute
for Microbial Disease, Osaka University, Japan [9]. Adoptive transfer
of fetal liver cells was performed according to a previously described
method [10]. Brie£y, embryos were generated from crosses of GFP
mice. Fetal livers were harvested from day 13.5 GFP embryos (where
day 0.5 is de¢ned as the morning the plugs were identi¢ed) and placed
in BMC media (Hank’s balanced salt solution, 10 mM HEPES, 2.5
fetal bovine serum). Single-cell suspensions were prepared by passage
through a 26-gauge needle. Recipient C57BL/6 male mice were irra-
diated using doses of 8 Gy and 4 Gy, separated by 3 h. Bone marrow
was reconstituted by injecting fetal liver cells (2U106 cells/200 Wl
media) intravenously through the tail vein. Three weeks after trans-
plantation, over 95% of the circulating white blood cells were GFP-
positive, indicating that the recipient C57BL/6 mice had completely
reconstituted with BMCs of GFP mouse origin.
2.2. Induction of pulmonary emphysema and treatment
After con¢rming GFP chimerism, lung emphysema was induced in
mice by intranasal instillation of porcine pancreas elastase (200 units/
kg; Sigma, St Louis, MO, USA), as previously described [1]. Three
weeks after elastase administration, mice exhibited emphysematous
changes in the lungs. At this point, mice were randomly divided
into four groups (each group n=5) and were administered either
vehicle only, ATRA (500 Wg/kg/day, intraperitoneally (i.p.) ; Sigma),
G-CSF, a factor known to mobilize hematopoietic and mesenchymal
lineage cells from bone marrow [11] (50 Wg/kg/day, subcutaneously
(s.c.); PeproTech, Rocky Hill, NJ, USA), or a combination of both
ATRA and G-CSF. All reagents were administered by daily injection
for 12 days, after which the mice were killed for analysis.
2.3. Histological analysis of recipient lungs
Pulmonary vasculature was £ushed with phosphate-bu¡ered saline
(PBS) to wash out the intravascular leukocytes, because leukocytes
remaining (most of them were GFP-positive) within the pulmonary
capillary disturb the histological evaluations. To £ush the pulmonary
vasculature, the right ventricle was punctured with a 23-gauge needle
(TERUMO, Tokyo, Japan). The pulmonary vessels were perfused in
situ with PBS at a pressure of 20 cmH2O. Then, recipient lungs were
¢xed with 4% paraformaldehyde^PBS at a transpulmonary pressure
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of 20 cmH2O. Fixed lungs were embedded in para⁄n and sectioned
using standard methods. Fixed lungs were also washed in sucrose^
PBS, embedded in ornithine carbamoyltransferase (OCT) compound,
and frozen in liquid nitrogen for cryosectioning. Para⁄n sections were
processed for hematoxylin and eosin staining or for immunohisto-
chemistry. GFP was detected using rabbit polyclonal anti-GFP anti-
body (Abcam, Cambridge, UK), with horseradish peroxidase (HRP)-
labelled goat anti-rabbit IgG (Vector, Burlingame, CA, USA) used as
the secondary antibody. Samples were subsequently incubated with
avidin-biotin HRP complex (ABC Elite, Vector). The ¢nal reaction
product was visualized with 3,3P-diaminobenzidine (Sigma). Sections
were counterstained with hematoxylin. The extent of the emphysem-
atous lesions was assessed by measuring the mean linear intercept
(Lm) using the method of Thurlbeck with some modi¢cations [12].
Brie£y, 20 ¢elds at 400U magni¢cation were randomly sampled on
two slides from each mouse, and point counting performed. The total
distance divided by the number of alveolar intercepts gave Lm. Cryo-
sections (10 Wm thick) were processed for immuno£uorescent staining.
Alveolar epithelial cells were identi¢ed using a murine monoclonal
antibody anti-cytokeratin 5 and 8 (Chemicon, Temecula, CA, USA)
and a goat Alexa £uor 350-conjugated anti-mouse antibody (Molec-
ular Probes, Eugene, OR, USA). Endothelial cells were identi¢ed us-
ing a rat biotin-conjugated monoclonal anti-murine CD34 antibody
(BD Pharmingen, San Diego, CA, USA) and 7-amino-4-methylcou-
marin-3-acetic acid (AMCA)-conjugated streptavidin (Immunotech,
Marseille, France). Hematopoietic cells were identi¢ed using a rat
phycoerythrin (PE)-conjugated anti-murine CD45 antibody (BD
Pharmingen). The number of GFP-positive and CD45-negative cells,
consistent with BMCs excluding intravascular or perivascular hema-
topoietic cells, was counted in alveolar walls of 200 separate alveoli
from each mouse (each group n=5). Histological evaluations were
performed blindly by three observers (K. Ishizawa, T. Suzuki, and
H. Kubo). In the present study, inter-observer di¡erences were less
than 5%, and the mean of the three values was obtained.
2.4. Cell sorting and £ow cytometry
A total of 0.5^1.0 ml of blood was obtained from each mouse. Red
blood cells were depleted using RBC lysis bu¡er (0.15 M NH4Cl, 0.01
M KHCO3, 0.1 mM ethylenediamine tetraacetic acid (EDTA)-2Na,
pH 7.2). Stem cell antigen-1 (Sca-1)þ peripheral blood cells were iso-
lated using the Magnetic Cell Sorting System with anti-Sca-1-coated
microbeads (Miltenvi Biotec, Bergisch Gladbach, Germany). Sorted
Sca-1þ cells were stained with £uorescein isothiocyanate (FITC)-la-
belled anti-murine Sca-1 antibody (BD Pharmingen) and PE-labelled
anti-murine fetal liver kinase-1 (Flk-1) (BD Pharmingen), and ana-
lyzed with a FACSCalibur £ow cytometer (Becton Dickinson, San
Jose, CA, USA). Cells were initially gated by propidium iodine (Sig-
ma, St. Louis, MO, USA) staining to restrict consideration to live
cells.
2.5. Statistical analysis
Data are expressed as the meanR standard error of the mean. Com-
parisons were made by analyses of variance, and when overall di¡er-
ences were identi¢ed, multiple contrasts with a Bonferroni adjustment
were used to identify which groups were signi¢cantly di¡erent. Statis-
tical signi¢cance was de¢ned as P6 0.05.
Fig. 1. ATRA and G-CSF reduced the extent of emphysematous
changes. A^E: Representative histological sections for each group.
Sections were stained with hematoxylin and eosin. Elastase treat-
ment induced emphysematous changes in murine lungs (B), com-
pared to non-treated lungs (A). Treatment with ATRA (C), G-CSF
(D), or both ATRA and G-CSF (E) increased alveolar septation
and reversed the manifestations of elastase-induced emphysema.
F: The alveolar Lm, used as a morphometric parameter of emphyse-
ma, showed that treatment with ATRA, G-CSF, or ATRA+G-CSF
reduced emphysematous changes. *P6 0.001, versus vehicle without
elastase, 2P6 0.001 versus vehicle with elastase, 3P6 0.001 versus
ATRA.
Fig. 2. BMCs are present in regenerated lung parenchyma following
elastase-induced emphysema. A^E: Para⁄n sections were immuno-
stained for GFP (brown). BMCs (GFPþ cells) are present in the al-
veolar cell walls (arrowheads). Scale bars, 50 Wm. F: Percentage of
GFPþ/CD453 cells in alveoli. *P6 0.001, versus vehicle without
elastase, 2P6 0.001 versus vehicle with elastase, 3P6 0.001 versus
ATRA.
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3. Results and discussion
Our results indicated that ATRA treatment improved em-
physema, as previously described [1] (Fig. 1A^C). Interest-
ingly, G-CSF treatment alone also provided a signi¢cant re-
duction in emphysema (Fig. 1D). For G-CSF-treated mice,
the alveolar Lm, used as a morphometric parameter of em-
physema [12], showed a 44% reduction compared to vehicle-
treated elastase-induced emphysematous mice (Fig. 1F). This
was the same degree of reduction as observed for ATRA-
treated mice (Fig. 1F). Combined treatment with G-CSF
and ATRA exhibited an additive e¡ect with a 73% reduction
in Lm (Fig. 1E,F).
To evaluate BMC distribution, we performed immunohis-
tochemical analysis using an anti-GFP antibody (Fig. 2A^E).
At baseline, only circulating white blood cells and alveolar
macrophages were GFP-positive (GFPþ), and almost no
GFPþ cells were observed in the alveolar walls (Fig. 2A).
While elastase administration induced a slight increase in
GFPþ cells in the alveolar walls (Fig. 2B,F), treatment with
G-CSF, ATRA, or both induced a signi¢cant increase in the
number of alveoli containing GFPþ cells (Fig. 2C^E). The
percentage of GFPþ cells per alveolus also increased in mice
treated with G-CSF, ATRA, or both (Fig. 2F). These results
suggested that the regenerated alveoli were comprised of
BMCs.
To con¢rm the cell type of the GFPþ cells, triple-color
immuno£uorescent staining was performed using CD45 to
mark hematopoietic cells and either cytokeratin to mark epi-
thelial cells [13] or CD34 to mark endothelial cells [14]. Flat
GFPþ/cytokeratinþ/CD453 cells were present in the alveolar
walls of ATRA- and/or G-CSF-treated lungs (Fig. 3A). Be-
cause the population of circulating GFPþ/CD453 cells in pe-
ripheral blood was very low (0.002%), this suggested that
BMCs had di¡erentiated into cells with an alveolar epithelial
phenotype. Similarly, £at GFPþ/CD34þ/CD453 cells were
also observed, which were suggestive of di¡erentiation toward
pulmonary capillary endothelial cells (Fig. 3B). Although
CD45þ cells were identi¢ed in the same lung sections, no cells
stained simultaneously for both CD45 and cytokeratin, or for
both CD45 and CD34. We also performed simultaneous
staining for cytokeratin and CD34. As seen in Fig. 3C, cyto-
keratin and CD34 antibodies stained separate cell popula-
tions. Thus, our data suggested that BMCs play an important
role in the regeneration of lung parenchyma.
To evaluate the role of G-CSF on BMC mobilization, we
focused on endothelial progenitor cells (EPCs), because they
are present in peripheral blood and can di¡erentiate into ma-
ture endothelial cells [2]. Bone marrow-derived circulating
EPCs express both hematopoietic stem cell and hemangioblast
markers, such as Sca-1 and Flk-1/VEGF-R2. Flow cytometry
demonstrated that G-CSF treatment induced a three-fold in-
Fig. 3. BMCs di¡erentiate into cells with an alveolar epithelial phenotype or a capillary endothelial phenotype. A^C: Immunostaining for cyto-
keratin and CD45 (A), CD34 and CD45 (B), or cytokeratin and CD34 (C). Color staining: GFP, green; cytokeratin or CD34, blue; CD45,
red (A and B). GFP, green; cytokeratin, blue; CD34, red (C). A and B: Note that GFPþ/cytokeratinþ/CD453 and GFPþ/CD34þ/CD453 cells
are present in the alveolar walls (turquoise blue, arrowheads in merged panels). C: Simultaneous staining for cytokeratin and CD34 was also
performed. Note that GFPþ/cytokeratin3/CD34þ cell (yellow, arrow in merged panel) and GFPþ/cytokeratinþ/CD343 cell (turquoise blue, ar-
rowheads in merged panel) are present. Scale bars, 10 Wm.
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crease in the percentage of circulating Sca-1þ/Flk-1þ cells in
peripheral blood (0.041R 0.017% in control group versus
0.123R 0.031% in G-CSF group; n=7; P6 0.001). In con-
trast, the percentage of circulating EPCs was not increased
by ATRA treatment (0.058 R 0.024%; n=7; P=0.31). This
suggested that the mobilization of hematopoietic and mesen-
chymal cells from bone marrow by G-CSF promoted lung
regeneration. Also, the roles of ATRA and G-CSF on lung
regeneration appear to be di¡erent, which would explain why
the combined treatment of G-CSF and ATRA had an addi-
tive e¡ect. BMCs were present in elastase-treated lungs be-
cause of the elastase-induced in£ammatory responses (Fig.
2B,F). Although ATRA did not induce EPC mobilization
within the circulation, this presence of BMCs may play a
role on ATRA-induced lung regeneration and an increase in
the number of GFPþ/CD453 cells in ATRA-treated lungs
(Fig. 2C,F).
Recently, several studies reported that bone marrow cells
adopted the phenotype of other cell types by spontaneous cell
fusion rather than by di¡erentiation [15^17]. In our study, the
question as to whether GFPþ/cytokeratinþ/CD453 alveolar
epithelial cells or GFPþ/CD34þ/CD453 endothelial cells
were generated by BMC di¡erentiation or fusion with existing
parenchymal remains unanswered.
While a clinical pilot study of ATRA treatment in patients
with pulmonary emphysema has been reported, ATRA treat-
ment failed to show signi¢cant improvement in the lung struc-
ture as evaluated by CT scan or lung function data [18]. As
most of the pulmonary emphysema patients used in the study
were elderly, this failure may be due to decreased numbers of
progenitor cells in the lung parenchyma or bone marrow. Our
present ¢ndings may arouse further interest into the therapeu-
tic possibilities of BMCs in the amelioration of pulmonary
emphysema.
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